Myeloma

The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.

Here’s a look back at blood cancer approvals from the summer of 2023.

As majority leader Steve Scalise announces his new cancer diagnosis and author Ibram X. Kendi reveals that he is cancer free, this is what’s happening in the oncology space this week.

Elrexfio has been shown to provide patients with relapsed/refractory multiple myeloma who previously received four or more lines of therapy with a response that may last at least 15 months, an expert explained.

The recent FDA approval of Talvey for heavily pretreated multiple myeloma results in an improved response to therapy and a manageable side effect profile.

The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy.

The FDA granted an accelerated approval for Talvey to treat patients with relapsed/refractory multiple myeloma.

Momelotinib led to symptom, spleen and anemia benefits for patients with previously treated myelofibrosis, according to updated study findings.

Supervised exercise can help to improve the immune system for patients with myeloma, recent research showed.

Maintenance Darzalex, with or without Pomalyst was safe and efficacious in treating patients with relapsed myeloma who underwent salvage autologous hematopoietic stem cell transplant.

Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.

Cryopreserved stem cells led to a higher rate of relapse in patients with blood cancer, though there was no difference in survival, research showed.

Mixed in the boxes of appointments and cancer treatments are milestones that uplift my spirits and are unique to my healing journey.

Watch Dr. Brandon J Blue, Dr. Surbhi Sidana, Dr. Kenneth H. Shain and Mary Derome answer questions about the future of treatment during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Kenneth H. Shain, from Moffitt Cancer Center, discuss the future of myeloma treatment, including BiTE therapy, during the CURE Educated Patient Multiple Myeloma Summit.

Patients with myeloma who are being treated with Tecvayli must discuss symptoms of cytokine release syndrome with their providers as soon as they happen.

Watch Dr. Surbhi Sidana, from Stanford Medicine, discuss CAR-T cell therapy during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Brandon J Blue, Dr. Dickran Kazandjian and Dr. Marc J. Braunstein answer questions about disease management during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Marc Braunstein, from NYU Langone Hospital, discuss the role of bone marrow transplant during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Dickran Kazandjian, from Miami Health System, discuss updates in newly diagnosed disease during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Ariel Grajales-Cruz and Dr. Brandon J Blue answer questions about myeloma during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Brandon Blue, from Moffitt Cancer Center, discuss health disparities during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Ariel F. Grajales-Cruz, from Moffitt Cancer Center, discuss updates in MGUS and smoldering disease during the CURE Educated Patient Multiple Myeloma Summit.

The FDA has accepted a supplemental Biologics License Application for moving up the use of Abecma, a CAR-T cell therapy, for adult patients with multiple myeloma.

Omisirge is an umbilical cord blood-based therapy that may prevent infection in patients with blood cancer undergoing stem cell transplant.

The Food and Drug Administration granted OM-301 an Orphan Drug Designation for the treatment of patients with myeloma.

A multiple myeloma survivor discusses how continued minimal residual disease negativity made her feel more confident in coming off of maintenance therapy.

I’m more than six years out from my myeloma diagnosis and realized that I’m capable of more than just surviving.

Triplet therapy demonstrates improved remission and survival rates, with manageable side effects for patients who are ineligible for transplant.